Biotechnology
WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index
SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...
Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries
SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9M...
SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit
First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit...
TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody
HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared i...
WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List
SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...
BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy
* A leader in creating jobs through the advancement of RNA-based therapeutics * A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South K...
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates
Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...
Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL
SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...
Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...
HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company deploying its NITROME platform to buil...
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL)...
Shenzhen Holds 2022 Global Investment Promotion Conference to Build a Magnet for International Investors
SHENZHEN, China, Dec. 8, 2022 /PRNewswire/ -- Shenzhen welcomes outstanding investors from all over the world. The 2022 Shenzhen Global Investment Promotion Conference will be held inShenzhen, China on December 9. A number of major projects in the fields of information technology, artificial int...
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now available in 5 major European countries –Germany, the UK, Italy, Spain, France – and 10 other key markets PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global ...
ReviR Therapeutics to Present at RNA Targeted Drug Discovery Summit
SAN FRANCISCO, Calif., Dec. 8, 2022 /PRNewswire/ -- ReviR Therapeutics (ReviR), a biotechnology company developing small molecule therapies targeting RNA, today announced an upcoming presentation at the 5th Annual RNA Targeted Drug Discovery conference taking placeDecember 13-15, 2022 in Boston, ...
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been desi...
Week's Top Stories
Most Reposted
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
[Picked up by 313 media titles]
2024-10-25 18:29International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
[Picked up by 300 media titles]
2024-10-25 22:482024 Malaysia E-commerce Product Selection Expo Reaches Major Milestone Attracting Leading Brands and Businesses From China
[Picked up by 300 media titles]
2024-10-25 07:00RuggON Showcases Latest Mining Technology at IMARC 2024
[Picked up by 294 media titles]
2024-10-28 14:32TotalEnergies ENEOS Completes a 1.8 MWp Floating Solar Photovoltaic System Project, a Second Collaboration with S. Kijchai Enterprise in Thailand
[Picked up by 288 media titles]
2024-10-29 11:24